Table 1 Main characteristics of the studies included in the meta-analysis
Study ID | Location | Study type | Administration | Dosage | Total cases | Gender, male/female | Age | Classification | Stage | Course | Outcomes | Recurrence (follow-up) | adverse events | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PV | AP | EP | PP | Stabe | Unstable | Cured cases | Effective cases | |||||||||||
Liu et al. (1980) | China | Retrospective study | Intravenous | 0.3 mg/kg, once | 18 | 7/11 | 27.5 ± 9.3 | NR | NR | NR | NR | 2 | 16 | 11.4 ± 7.0(3 months-28 years) | 5 | 15 | 3(NR) | NR |
Liu et al. (1983) | China | Retrospective study | Intravenous | 0.1 mg/kg, once | 250 | 152/98 | 9–50 | 230 | 5 | 7 | 8 | 135 | 115 | 2 months-25 years | 85 | 248 | 45(6 months) | 0 |
Wang et al. (1985) | China | Single-arm study | Intravenous | 0.4 mg/kg, once; 0.2 mg/kg, once; 0.15 mg/kg, once | 242 | 129/113 | 10–69 | 238 | 1 | 1 | 2 | 66 | 176 | 1 month-35 years | 163 | 210 | 6(6 months) 8(1 year) 19(2.5 years) | NR |
Zhou et al. (1986) | China | Retrospective study | Intravenous | 0.2 mg/kg, once | 100 | 60/40 | 9–55 | 99 | 0 | 0 | 1 | 74 | 26 | 20 days-28 years | 56 | 85 | 2(6 months) | NR |
Qing et al. (1989) | China | Retrospective study | Intravenous | 2ml, once every two week | 200 | NR | NR | 200 | 0 | 0 | 0 | NR | NR | NR | 95 | 187 | NR | NR |
Chen et al. (1989) | China | Retrospective study | Oral + Extra-apply | unclear dose; once | 670 | NR | NR | NR | NR | NR | NR | NR | NR | 1 month-40 years | 203 | 589 | NR | 74.57% |
Kang et al. (1999) | China | Single-arm study | Oral + Extra-apply | 2 g, twice in a course of treatment | 210 | 142/68 | 13–58 | NR | NR | NR | NR | NR | NR | several months:25, 2–3 years:140, >4 years: 45 | 147 | 202 | 8(4 years) | NR |
Zhou et al. (2011) | China | non-RCT study | Oral | 3.3 g, three times in a course of treatment | 58 | 36/22 | 14–53 | 58 | 0 | 0 | 0 | NR | NR | 3 months- 26 years | 34 | 57 | NR | 4 |
Yang et al. (2018) | China | RCT study | Oral + Extra-apply | 100 mg, bid | 30 | 17/13 | 34.6 ± 3.5 | 30 | 0 | 0 | 0 | NR | NR | 6.6 ± 1.5 months | 3 | 28 | NR | NR |